You are here

RNAi

After big year, RNAi drugmakers compete to prove what comes next

After big year, RNAi drugmakers compete to prove what comes next

BioPharma Dive

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

Flag link:

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval

Fierce Pharma

John Maraganore

Flag link:

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

With trial win, Alnylam to seek approval for first treatment of rare kidney disease

Biopharma Dive

clincial trials

Primary Hyperoxaluria

Flag link:

3 Soaring Biotech Stocks to Watch in December

3 Soaring Biotech Stocks to Watch in December

Motley Fool

Arrowhead Pharmaceuticals

Adverum Biotechnologies

Flag link:

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class

Motley Fool

Flag link:

FDA's rapid review pace nets an early approval for Alnylam's second drug

FDA's rapid review pace nets an early approval for Alnylam's second drug

Biopharma Dive

Flag link:

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Endpoints

Flag link:

Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Fierce Biotech

Dicerna Pharmaceuticals

Flag link:

Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn

Fierce Pharma

Flag link:

RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round

RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round

CP Wire

cholangiocarcinoma

hepatocellular carcinoma

Flag link:

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Xconomy

Flag link:

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise

Endpoints

John Maraganore

Flag link:

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Data in Hand, Alnylam To Seek OK For Second RNAi Drug

Xconomy

acute hepatic porphyria

Flag link:

Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018

Motley Fool

Arrowhead Pharmaceuticals

Flag link:

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

BioPharma Dive

John Maraganore

Flag link:

Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November

Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November

Motley Fool

Arrowhead Pharmaceuticals

Flag link:

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst

Fierce Pharma

hATTR amyloidosis

Flag link:

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Pharmaceutical Business Review

Flag link:

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug

Fierce Biotech

Flag link:

RNAi company Dicerna raises $100M follow-on

RNAi company Dicerna raises $100M follow-on

BioCentury

Dicerna Pharmaceuticals

Flag link:

Pages